Fisetin Interactions: Alcohol, Caffeine, Food & Other Compounds — What the Literature Reports

Fisetin is a plant flavonol studied mainly as a senolytic and anti-inflammatory compound. Questions about how it behaves alongside other substances — alcohol, caffeine, a meal, a fasting window, or another drug — are common, but the published record is uneven. Some pairings have been examined directly in experiments; most have not. This page distinguishes the two categories explicitly and never converts mechanism into a recommendation.

This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision. Nothing here describes a protocol, a combination strategy, or a timing scheme.

How the Evidence Splits

Three kinds of statements appear below, and they are not equivalent:

• Measured findings. An experiment placed fisetin (or a flavonoid panel including fisetin) alongside another substance and reported an outcome.
• Mechanistic reasoning (labelled as such). No combination study exists, but researchers describe a shared enzyme, transporter or pathway that could plausibly matter. This is inference, not evidence of an interaction.
• Absence. The verified literature reviewed for this page contained no study on the pairing at all.

Fisetin and Alcohol

Among the verified papers assembled for this page, none administered ethanol together with fisetin, and none reported a pharmacokinetic or toxicological outcome for that combination in animals or humans. That absence is the finding; it should not be read as reassurance or as warning.

Mechanistic reasoning, labelled as such: researchers who discuss flavonoid–ethanol questions generally point to the liver, because both ethanol metabolism and flavonoid conjugation occur there, and to oxidative-stress pathways, because flavonols are typically characterised by their redox activity. Fisetin's reported biology includes regulation of ferroptosis through Sirt6-mediated deacetylation in an amyloid-β neuronal model (PMID 40759059) and suppression of inflammatory signalling — for example, targeting myeloid differentiation factor 88 in lipopolysaccharide-induced acute lung injury (PMID 41526707). Those papers examined fisetin alone; extending them to alcohol co-exposure is speculation, and the cited work does not test it.

Fisetin and Caffeine

No study in the verified set gave fisetin and caffeine together or measured caffeine levels in the presence of fisetin. What does exist is enzyme-level data on flavonoids and cytochrome P450 1A1: a 2020 in vitro investigation characterised human CYP1A1 inhibition by flavonoids and reported inhibitory activity within that compound class (PMID 31655123).

Mechanistic reasoning, labelled as such: CYP1A-family enzymes are the route by which several xenobiotics, including methylxanthines, are cleared, so investigators who see flavonoid inhibition of CYP1A1 in a cell-free or cell-based assay (PMID 31655123) commonly raise the theoretical question of altered clearance for co-administered substrates. That is a hypothesis generated by enzymology, not a measured caffeine interaction. In vitro inhibition constants do not automatically translate to oral exposure in a whole organism, where absorption, first-pass conjugation and tissue distribution intervene. The cited paper reported enzyme inhibition; it did not report a clinical consequence.

Fisetin, Food and Fasting

The verified literature reviewed here did not include a human study comparing fisetin taken with a meal against fisetin taken in a fasted state, and none reported bioavailability figures under either condition.

What has been published is formulation and membrane work. A 2022 study prepared flavonoid-loaded human serum albumin nanoparticles and examined their permeation across model membrane bilayers, an approach researchers use because flavonol absorption is limited by poor aqueous solubility (PMID 36155787). The rationale for such carrier systems is itself an acknowledgement that unformulated flavonols cross biological membranes inefficiently.

Mechanistic reasoning, labelled as such: because flavonols are lipophilic, investigators frequently hypothesise that dietary lipid affects their solubilisation, and because glucuronidation and sulfation occur in the intestinal wall and liver, they hypothesise that gut transit conditions affect how much parent compound reaches circulation. The nanoparticle permeation study (PMID 36155787) speaks to the membrane-crossing problem in a model system; it did not measure meals, fasting windows, or human plasma levels.

Why fasting comes up at all

Fisetin entered wide discussion after a 2018 report in EBioMedicine identified it as a senotherapeutic that extended health and lifespan in the models studied (PMID 30279143). Because caloric restriction and fasting are separately studied in ageing biology, the two topics are often discussed side by side. The senotherapeutic report examined fisetin itself (PMID 30279143); it did not test fisetin against a fasting intervention, and no combined comparison appears in the verified set.

Fisetin with Other Compounds: What Was Actually Tested

Doxorubicin

This is the best-documented fisetin combination in the cited literature, and it comes from oncology and toxicology rather than from supplement research. A 2025 study in the European Journal of Pharmacology examined a combination of doxorubicin with fisetin for the treatment of lymphoma and described the pairing as synergistic in the models used (PMID 39929420).

Separately, a 2023 GeroScience paper investigated increased cellular senescence in doxorubicin-induced murine ovarian injury and evaluated the effect of senolytics in that setting (PMID 36648735). Both were preclinical. Neither established a human regimen, and both were conducted in disease models with chemotherapy dosing that has no analogue outside oncology research.

Other senolytics and senescence research

The 2018 EBioMedicine work positioned fisetin within senotherapeutic research and reported health- and lifespan extension in the models examined (PMID 30279143). The murine ovarian injury study likewise assessed senolytic effect on senescence burden after doxorubicin exposure (PMID 36648735). Together these describe a research programme, not a combination protocol for humans.

Immune and mast-cell pathways

A 2023 study reported that fisetin alleviated chronic urticaria by inhibiting mast cell activation via MRGPRX2 (PMID 37410860). MRGPRX2 is a receptor implicated in non-IgE mast-cell activation by certain drugs, which is why researchers examine it when considering how compounds interact at the immune interface. The study characterised fisetin's effect on that pathway; it did not test fisetin alongside any specific co-administered medication.

Neuroinflammation pathways

A 2026 Neuropharmacology paper reported that fisetin targeted multiple signalling pathways to suppress microglia-mediated neuroinflammation and cognitive decline in an Alzheimer's disease model (PMID 41771399), and the ferroptosis work described Sirt6-mediated deacetylation as a regulatory node in amyloid-β-induced neuronal cell death (PMID 40759059). The relevance to interactions is indirect: a compound described as acting on multiple pathways (PMID 41771399) has more theoretical points of overlap with other agents, which is a reason researchers call for interaction studies rather than a substitute for having them.

Cancer-cell and antiviral screening work

A 2023 report described fisetin inducing apoptosis in human skin cancer cells through downregulation of MTH1 (PMID 36129011), and a 2024 bioinformatics analysis evaluated photoexcited natural flavonoid glycosides as inhibitors of oropharyngeal HPV oncoproteins (PMID 38466452). These are single-agent and computational studies; they are listed because they are sometimes cited in combination discussions, not because they tested combinations.

Genotoxicity Questions in the Flavonoid Class: What Studies Report

Interaction questions often shade into safety questions. Within the verified set, a 2005 Mutation Research paper examined the genotoxicity of phytoestrogens, a class assessment that has been discussed in relation to dietary flavonoids generally (PMID 15914213). That paper addressed a compound class in laboratory assays rather than fisetin-specific outcomes in people, and no adverse-event tables from human co-administration trials of fisetin with alcohol, caffeine or food appeared in the literature cited here.

The senotherapeutic report (PMID 30279143) and the preclinical combination studies (PMID 39929420, PMID 36648735) were conducted in animal and cell systems, so tolerability observations from them describe those systems only.

How to Read Interaction Claims About Fisetin

1. Ask whether the two substances were ever given together. For alcohol and caffeine with fisetin, the verified literature here contains no such experiment; enzyme data on flavonoids and CYP1A1 exist independently (PMID 31655123).
2. Check the system. Model membrane bilayers (PMID 36155787), cultured cells (PMID 36129011) and mice (PMID 36648735) answer different questions.
3. Separate synergy claims from clinical claims. A synergy described in a lymphoma model (PMID 39929420) is a preclinical observation.
4. Treat in silico work as hypothesis generation. The HPV oncoprotein analysis was computational (PMID 38466452).

The Short Version

Researchers have studied fisetin extensively on its own — as a senotherapeutic (PMID 30279143), as a modulator of microglial neuroinflammation (PMID 41771399), and as an inhibitor of MyD88-dependent inflammatory signalling (PMID 41526707) — but the interaction literature is thin. Where combinations were tested, they were chemotherapy pairings in preclinical models (PMID 39929420). Where they were not tested, as with alcohol, caffeine, meals and fasting, this page says so rather than filling the gap with inference presented as fact.

References

• Fisetin is a senotherapeutic that extends health and lifespan (EBioMedicine, 2018)
• Human CYP1A1 inhibition by flavonoids (Toxicology in vitro, 2020)
• Fisetin alleviates Aβ-induced neuronal cell ferroptosis by regulating Sirt6-mediated deacetylation modification (Journal of Neuroimmunology, 2025)
• Increased cellular senescence in doxorubicin-induced murine ovarian injury: effect of senolytics (GeroScience, 2023)
• Fisetin targets multiple signaling pathways to suppress microglia-mediated neuroinflammation and cognitive decline in Alzheimer's disease (Neuropharmacology, 2026)
• Fisetin Attenuates Lipopolysaccharide-Induced Acute Lung Injury by Targeting Myeloid Differentiation Factor 88 (Inflammation, 2026)
• Genotoxicity of phytoestrogens (Mutation Research, 2005)
• Fisetin induces apoptosis in human skin cancer cells through downregulating MTH1 (Journal of Biomolecular Structure & Dynamics, 2023)
• Bioinformatics analysis of photoexcited natural flavonoid glycosides as the inhibitors for oropharyngeal HPV oncoproteins (AMB Express, 2024)
• Permeation of flavonoid loaded human serum albumin nanoparticles across model membrane bilayers (International Journal of Biological Macromolecules, 2022)
• Synergistic combination of doxorubicin with fisetin for the treatment of lymphoma (European Journal of Pharmacology, 2025)
• Fisetin alleviates chronic urticaria by inhibiting mast cell activation via MRGPRX2 (Journal of Pharmacy and Pharmacology, 2023)